Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1971 1
1972 1
1974 1
1976 1
1978 1
1983 1
1984 1
1987 1
1988 2
1991 1
1992 1
2000 2
2001 1
2002 3
2003 3
2004 2
2005 2
2007 3
2008 4
2009 2
2010 1
2011 2
2012 1
2013 4
2014 4
2015 3
2016 5
2017 4
2018 3
2019 3
2020 3
2021 5
2022 5
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Single-Molecule FRET X.
Filius M, van Wee R, Joo C. Filius M, et al. Among authors: van wee r. Methods Mol Biol. 2024;2694:203-213. doi: 10.1007/978-1-0716-3377-9_10. Methods Mol Biol. 2024. PMID: 37824006
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Full-length single-molecule protein fingerprinting.
Filius M, van Wee R, de Lannoy C, Westerlaken I, Li Z, Kim SH, de Agrela Pinto C, Wu Y, Boons GJ, Pabst M, de Ridder D, Joo C. Filius M, et al. Among authors: van wee r. Nat Nanotechnol. 2024 May;19(5):652-659. doi: 10.1038/s41565-023-01598-7. Epub 2024 Feb 13. Nat Nanotechnol. 2024. PMID: 38351230
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
M.B. Lond. (failed).
Marcovitz S, Wee R, Chan J, Hardy J. Marcovitz S, et al. Among authors: wee r. Lancet. 1978 Sep 30;2(8092 Pt 1):719-20. Lancet. 1978. PMID: 80641 Free PMC article.
Ocular pathology. Preface.
Miller JW, Wee R. Miller JW, et al. Among authors: wee r. Int Ophthalmol Clin. 2009 Winter;49(1):xv. doi: 10.1097/01.iio.0000342975.50125.00. Int Ophthalmol Clin. 2009. PMID: 19125058 No abstract available.
Teaching data science to medical trainees.
Wee R, Soh E, Giles D. Wee R, et al. Clin Teach. 2021 Aug;18(4):384-385. doi: 10.1111/tct.13391. Epub 2021 Jun 7. Clin Teach. 2021. PMID: 34101355 No abstract available.
84 results